St. Elizabeth Healthcare First in Kentucky to Implant New Device To Treat Abnormal Heart Rhythm

Our Bureau

Doctors with the Florence Wormald Heart & Vascular Institute at St. Elizabeth Healthcare  are the first in Kentucky and the Greater Cincinnati region to implant the Aurora EV-ICD™ system — a new device to treat fast or irregular heartbeats and prevent sudden cardiac arrest. J. Christian Hays, MD, Director of Cardiac Electrophysiology at St. Elizabeth Healthcare, performed the […]

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

Our Bureau

AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a compelling overall response rate per independent central review (ICR) of […]

NUTEX HEALTH LAUNCHES INNOVATIVE PSYCHIATRIC SERVICES AT TEXAS HOSPITAL

Our Bureau

Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that SE Texas ER & Hospital will be incorporating 24/7 behavioral health services along with emergency […]

European Medicines Agency Validates Type II Variation for Astellas’ XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Our Bureau

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the European Medicines Agency (EMA) has validated its Type II variation for XTANDI® (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk […]

Subscribe Now